News and reporting on lung cancer.
The study said that a revision of USPSTF's guidelines would lead to more equitable lung cancer screening for African American smokers at high risk for the disease.
The firm said it needs more time to ensure that the DetermaVu assay is providing the most consistent and sensitive results for patients.
Almac said that the assay will be used in a clinical study of repotrectinib (TPX-0005), an investigational, next-generation tyrosine kinase inhibitor.
The company said adopters are ordering tests in areas of great interest, like CTC and blood biomarker monitoring, despite a lack of reimbursement.
Shares jumped nearly 90 percent today after the firm said this morning that it has commercially launched its Target Selector NGS Lung Panel assay.
The firm is conducting validation studies on its lung cancer test and continues to anticipate commercializing it in the second half of this year.
Investigators from a variety of clinical sites found that the company's liquid biopsy test was more successful in finding actionable mutations in patients than tumor tissue.
The diagnostic can now be used to identify a wider range of patients with stage III or metastatic NSCLC who may benefit from first-line treatment with Keytruda.
The test is designed to measure levels of seven auto-antibodies to tumor-associated antigens and can detect all forms of lung cancer at any stage.
Clinical researchers at AACR discussed a wide range of approaches focusing on several different potential use-cases in the detection or assessment of early cancers.